Mayken Visser1,2, René van Oerle2, Hugo Ten Cate2,3, Volker Laux1, Nigel Mackman4, Stefan Heitmeier1, Henri M H Spronk2. 1. From the Bayer AG, Cardiovascular Research, Wuppertal, Germany (M.V., V.L., S.H.). 2. Laboratory for Clinical Thrombosis and Haemostasis, Departments of Biochemistry and Internal Medicine, Cardiovascular Research Institute Maastricht, Maastricht University, the Netherlands (M.V., R.v.O., H.t.C., H.M.H.S.). 3. Center for Thrombosis and Hemostasis (CTH), University Medical Center of the Johannes Gutenberg-University Mainz, Germany (H.t.C.). 4. Thrombosis and Hemostasis Program, Division of Hematology and Oncology, Department of Medicine, University of North Carolina at Chapel Hill (N.M.).
Abstract
OBJECTIVES: FXIa (factor XIa) induces clot formation, and human congenital FXI deficiency protects against venous thromboembolism and stroke. In contrast, the role of FXI in hemostasis is rather small, especially compared with FIX deficiency. Little is known about the cause of the difference in phenotypes associated with FIX deficiency and FXI deficiency. We speculated that activation of FIX via the intrinsic coagulation is not solely dependent on FXI(a; activated FXI) and aimed at identifying an FXI-independent FIX activation pathway. Approach and Results: We observed that ellagic acid and long-chain polyphosphates activated the coagulation system in FXI-deficient plasma, as could be demonstrated by measurement of thrombin generation, FIXa-AT (antithrombin), and FXa-AT complex levels, suggesting an FXI bypass route of FIX activation. Addition of a specific PKa (plasma kallikrein) inhibitor to FXI-deficient plasma decreased thrombin generation, prolonged activated partial thromboplastin time, and diminished FIXa-AT and FXa-AT complex formation, indicating that PKa plays a role in the FXI bypass route of FIX activation. In addition, FIXa-AT complex formation was significantly increased in F11-/- mice treated with ellagic acid or long-chain polyphosphates compared with controls and this increase was significantly reduced by inhibition of PKa. CONCLUSIONS: We demonstrated that activation of FXII leads to thrombin generation via FIX activation by PKa in the absence of FXI. These findings may, in part, explain the different phenotypes associated with FIX and FXI deficiencies.
OBJECTIVES: FXIa (factor XIa) induces clot formation, and human congenital FXI deficiency protects against venous thromboembolism and stroke. In contrast, the role of FXI in hemostasis is rather small, especially compared with FIX deficiency. Little is known about the cause of the difference in phenotypes associated with FIX deficiency and FXI deficiency. We speculated that activation of FIX via the intrinsic coagulation is not solely dependent on FXI(a; activated FXI) and aimed at identifying an FXI-independent FIX activation pathway. Approach and Results: We observed that ellagic acid and long-chain polyphosphates activated the coagulation system in FXI-deficient plasma, as could be demonstrated by measurement of thrombin generation, FIXa-AT (antithrombin), and FXa-AT complex levels, suggesting an FXI bypass route of FIX activation. Addition of a specific PKa (plasma kallikrein) inhibitor to FXI-deficient plasma decreased thrombin generation, prolonged activated partial thromboplastin time, and diminished FIXa-AT and FXa-AT complex formation, indicating that PKa plays a role in the FXI bypass route of FIX activation. In addition, FIXa-AT complex formation was significantly increased in F11-/- mice treated with ellagic acid or long-chain polyphosphates compared with controls and this increase was significantly reduced by inhibition of PKa. CONCLUSIONS: We demonstrated that activation of FXII leads to thrombin generation via FIX activation by PKa in the absence of FXI. These findings may, in part, explain the different phenotypes associated with FIX and FXI deficiencies.
Authors: Michał B Ponczek; Aleksandr Shamanaev; Alec LaPlace; S Kent Dickeson; Priyanka Srivastava; Mao-Fu Sun; Andras Gruber; Christian Kastrup; Jonas Emsley; David Gailani Journal: Blood Adv Date: 2020-12-22
Authors: Jun Wan; Nadira Vadaq; Joke Konings; Martin Jaeger; Vinod Kumar; Bas de Laat; Leo Joosten; Mihai G Netea; Andre J van der Ven; Philip G de Groot; Quirijn de Mast; Mark Roest Journal: J Thromb Haemost Date: 2021-09-28 Impact factor: 16.036
Authors: Alejandro Pallares Robles; Vincent Ten Cate; Andreas Schulz; Jürgen H Prochaska; Steffen Rapp; Thomas Koeck; Marina Panova-Noeva; Stefan Heitmeier; Stephan Schwers; Kirsten Leineweber; Hans-Jürgen Seyfarth; Christian F Opitz; Henri Spronk; Christine Espinola-Klein; Karl J Lackner; Thomas Münzel; Miguel A Andrade-Navarro; Stavros V Konstantinides; Hugo Ten Cate; Philipp S Wild Journal: Sci Rep Date: 2022-06-13 Impact factor: 4.996
Authors: Rida A Malik; Ji Zhou; James C Fredenburgh; Tammy K Truong; Jeff R Crosby; Alexey S Revenko; Jeffrey I Weitz Journal: Blood Adv Date: 2021-09-28
Authors: Fatmah S Alqahtany; Farjah H Algahtani; Mashael M Alshebly; Thamer S Albegamy; Essam S Alghamdi; Mohammed A Alnakhli; Fatimah M Madkhaly; Abdullah A Alharbi; Nawaf A Alqahtani Journal: Saudi J Biol Sci Date: 2021-01-08 Impact factor: 4.219
Authors: Michael W Henderson; Franciele Lima; Carla Roberta Peachazepi Moraes; Anton Ilich; Stephany Cares Huber; Mayck Silva Barbosa; Irene Santos; Andre C Palma; Thyago Alves Nunes; Raisa Gusso Ulaf; Luciana Costa Ribeiro; Ana Flavia Bernardes; Bruna Bombassaro; Sergio San Juan Dertkigil; Maria Luiza Moretti; Sidney Strickland; Joyce M Annichino-Bizzacchi; Fernanda Andrade Orsi; Eli Mansour; Licio A Velloso; Nigel S Key; Erich Vinicius De Paula Journal: Blood Adv Date: 2022-06-14
Authors: Katherine J Kearney; Juliet Butler; Olga M Posada; Clare Wilson; Samantha Heal; Majid Ali; Lewis Hardy; Josefin Ahnström; David Gailani; Richard Foster; Emma Hethershaw; Colin Longstaff; Helen Philippou Journal: Proc Natl Acad Sci U S A Date: 2021-01-19 Impact factor: 12.779